Profusa's Losses Mount Post-Merger Amid Nasdaq Delisting Threat

Ticker: NVACW · Form: 10-Q · Filed: Nov 19, 2025 · CIK: 1859807

Sentiment: bearish

Topics: Biotechnology, Medical Devices, Going Concern, Nasdaq Listing Rules, Equity Financing, Mergers and Acquisitions, Working Capital Deficit

Related Tickers: NVACW, PFSA

TL;DR

**Profusa is burning cash at an alarming rate post-merger, and despite new financing, its Nasdaq listing is on thin ice, making it a high-risk bet.**

AI Summary

Profusa, Inc. (NVACW) reported a significant net loss of $(27.256) million for the nine months ended September 30, 2025, a substantial increase from $(6.978) million in the same period of 2024. Operating expenses surged to $24.136 million for the nine months ended September 30, 2025, up from $3.518 million in 2024, primarily driven by a massive increase in general and administrative expenses to $22.587 million. The company's cash position improved to $3.009 million as of September 30, 2025, from $191 thousand at December 31, 2024, largely due to $14.937 million in financing activities, including proceeds from an Equity Line of Credit (ELOC) and convertible loans. Profusa completed a business combination with NorthView Acquisition Corporation on July 11, 2025, and subsequently changed its name. Despite securing a $100 million Committed Equity Facility with Ascent Partners Fund LLC, the company faces a working capital deficit of approximately $(19.3) million and has received a Nasdaq notice for failing to maintain a minimum market value of listed securities (MVLS) of $50 million, with a compliance deadline of March 10, 2026. The strategic outlook includes commercializing the Lumee Oxygen Platform in Europe in early 2026 and leveraging its Bitcoin treasury strategy for liquidity.

Why It Matters

Profusa's substantial net loss of $(27.256) million and working capital deficit of $(19.3) million signal significant financial instability, raising red flags for investors. The recent business combination with NorthView Acquisition Corporation and the $100 million ELOC with Ascent Partners Fund LLC provide some capital, but the company's ability to effectively deploy these funds for product commercialization, especially the Lumee Oxygen Platform, will be critical. The Nasdaq delisting notice due to failing the $50 million MVLS rule adds competitive pressure and could severely impact investor confidence and future fundraising capabilities, making it harder to compete with established medical device companies.

Risk Assessment

Risk Level: high — Profusa has a working capital deficit of approximately $(19.3) million and incurred a net loss of $(27.256) million for the nine months ended September 30, 2025, indicating severe financial distress. Furthermore, the company received a Nasdaq notice on September 11, 2025, for failing to maintain a minimum market value of listed securities of $50 million, with a compliance deadline of March 10, 2026, directly threatening its public trading status.

Analyst Insight

Investors should exercise extreme caution and consider avoiding NVACW given the significant financial losses, working capital deficit, and the immediate threat of Nasdaq delisting. Monitor the company's progress on commercializing the Lumee Oxygen Platform and its ability to regain Nasdaq compliance by March 10, 2026, before considering any investment.

Financial Highlights

debt To Equity
Not Disclosed
revenue
Not Disclosed
operating Margin
Not Disclosed
total Assets
$4.250M
total Debt
$38.210M
net Income
$(27.256)M
eps
Not Disclosed
gross Margin
Not Disclosed
cash Position
$3.009M
revenue Growth
Not Disclosed

Key Numbers

Key Players & Entities

FAQ

What is Profusa, Inc.'s current financial health as of September 30, 2025?

Profusa, Inc. reported a net loss of $(27.256) million for the nine months ended September 30, 2025, and has a working capital deficit of approximately $(19.3) million. The company's cash balance improved to $3.009 million, primarily due to $14.937 million in financing activities.

Why did Profusa, Inc. receive a notice from Nasdaq?

Profusa, Inc. received a notice from Nasdaq on September 11, 2025, because its market value of listed securities (MVLS) fell below the minimum $50,000,000 requirement of Nasdaq Listing Rule 5450(b)(2)(A). The company has until March 10, 2026, to regain compliance.

What is the significance of the business combination with NorthView Acquisition Corporation for Profusa?

The business combination with NorthView Acquisition Corporation, completed on July 11, 2025, resulted in Legacy Profusa becoming a wholly-owned subsidiary of Northview, which subsequently changed its name to Profusa, Inc. This transaction was a key event in the company's corporate structure and financing strategy.

How is Profusa, Inc. addressing its liquidity challenges?

Profusa, Inc. is addressing liquidity challenges through a $100,000,000 Committed Equity Facility with Ascent Partners Fund LLC, from which it has already sold approximately $3.5 million in common stock. Additionally, the company has a Bitcoin treasury strategy, purchasing 8.53 coins for $1.0 million, which may act as a source of liquidity.

What are Profusa, Inc.'s key product development efforts?

Profusa, Inc.'s key product development efforts are focused on its Lumee Oxygen Platform, which is designed to report tissue oxygen levels in the European Union, and its Lumee Glucose Platform, a system designed for continuous and long-term glucose monitoring in interstitial fluid.

What is the company's strategic outlook for revenue generation?

The company is currently working towards meeting regulatory requirements in Europe to commercialize the Lumee Oxygen reader, with the goal of generating revenues in early 2026. This commercialization effort is a primary focus for future revenue streams.

What is the impact of the increased general and administrative expenses on Profusa's financials?

General and administrative expenses surged to $22.587 million for the nine months ended September 30, 2025, compared to $2.169 million in the same period of 2024. This significant increase contributed heavily to the overall rise in operating expenses and the company's substantial net loss.

What should investors know about Profusa's common stock outstanding?

As of November 18, 2025, there were 65,680,958 shares of common stock, $0.0001 par value, outstanding. This represents a substantial increase from 8,593,991 shares outstanding at December 31, 2024, largely due to conversions of preferred stock and debt into common stock in connection with the merger and financing activities.

Does Profusa, Inc. have a going concern risk?

Yes, Profusa, Inc. has incurred significant net operating losses and has a working capital deficit of approximately $(19.3) million as of September 30, 2025. Management explicitly states that the liquidity from the PIPE Convertible Note is not sufficient to alleviate substantial doubt about the company's ability to continue as a going concern within one year.

What is the purpose of Profusa's digital asset investment?

Profusa, Inc. purchased 8.53 Bitcoin coins for a value of $1.0 million as of September 30, 2025, as part of its Bitcoin treasury strategy. While the company has a buy-and-hold investment strategy, this investment is also intended to act as a source of liquidity for operating cash flow requirements as needed.

Risk Factors

Industry Context

The medical device industry, particularly in areas like oxygen monitoring, is highly competitive and innovation-driven. Companies like Profusa are navigating a landscape that requires significant R&D investment, regulatory approvals (like FDA and CE marking), and effective commercialization strategies to gain market share. The trend towards connected health and remote patient monitoring presents opportunities, but also necessitates robust data security and integration capabilities.

Regulatory Implications

Profusa faces significant regulatory hurdles, including maintaining its Nasdaq listing by meeting the $50 million MVLS requirement by March 10, 2026. Failure to comply could lead to delisting, severely impacting liquidity and investor confidence. Additionally, commercializing its Lumee Oxygen Platform in Europe requires adherence to European regulatory standards (e.g., CE marking).

What Investors Should Do

  1. Monitor Nasdaq Compliance Efforts
  2. Evaluate Commercialization Strategy Execution
  3. Analyze Burn Rate and Future Funding Needs
  4. Assess Bitcoin Treasury Strategy Impact

Key Dates

Glossary

Equity Line of Credit (ELOC)
An agreement that allows a company to sell shares to an investor at a predetermined price over a period of time, providing flexible access to capital. (Profusa utilized an ELOC, contributing to its improved cash position, but it also represents potential future dilution.)
Market Value of Listed Securities (MVLS)
The total dollar value of a company's outstanding shares traded on an exchange. It's a key metric for exchanges to ensure a certain level of market capitalization. (Profusa's failure to meet the $50 million MVLS requirement has put its Nasdaq listing at risk.)
Working Capital Deficit
Occurs when a company's current liabilities exceed its current assets, indicating potential difficulty in meeting short-term obligations. (Profusa's deficit of approximately $(19.3) million highlights immediate liquidity concerns.)
Digital Assets
Refers to assets that exist in a digital or electronic form, such as cryptocurrencies. In this context, it likely refers to Profusa's Bitcoin holdings. (The company holds $972 thousand in digital assets as of September 30, 2025, part of its treasury strategy.)
Committed Equity Facility
A contractual agreement where an investor commits to purchase a certain amount of a company's stock over a specified period, often at the company's discretion. (Profusa has a $100 million facility with Ascent Partners Fund LLC, providing a potential source of future funding.)

Year-Over-Year Comparison

Profusa's financial performance has deteriorated significantly compared to the prior year's comparable period. The nine months ended September 30, 2025, saw a net loss of $(27.256) million, a sharp increase from $(6.978) million in 2024, driven by a dramatic rise in operating expenses, particularly G&A. While cash has increased substantially from $191 thousand to $3.009 million, this is primarily due to financing activities, not operational improvements. The company also faces new risks, including a working capital deficit of $(19.3) million and a Nasdaq delisting notice, which were not present in the prior reporting period.

Filing Stats: 4,683 words · 19 min read · ~16 pages · Grade level 18.1 · Accepted 2025-11-19 17:19:05

Key Financial Figures

Filing Documents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 1 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months and Nine Months Ended September 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Deficit for the Three Months and Nine Months ended September 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 (Unaudited) 5 Notes to the Condensed Consolidated Financial Statements (Unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 48 Item 4. Control and Procedures 48

– OTHER INFORMATION

PART II – OTHER INFORMATION 50 Item 1.

Legal Proceedings

Legal Proceedings 50 Item 1A. R isk Factors 50 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 61 Item 3. Defaults Upon Senior Securities 61 Item 4. Mine Safety Disclosures 61 Item 5. Other Information 61 Item 6. Exhibits 62

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PROFUSA, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE AMOUNTS) September 30, 2025 (UNAUDITED) December 31 2024 Assets Current assets: Cash 3,009 191 Prepaid expenses and other current assets 214 69 Digital assets 972 — Total current assets 4,195 260 Deferred offering costs — 2,757 Other non-current assets 55 56 Total assets 4,250 3,073 Liabilities, and stockholders' deficit Current liabilities: Accounts payable 6,982 4,954 Excise tax payable 1,957 — Accrued liabilities 7,848 3,968 Due to related party 41 — Convertible notes payable Convertible debt payable (including loans and notes payable to a related party of $ 4,127 and $ 25,056 as of September 30, 2025 and December 31, 2024, respectively) 4,281 45,921 Promissory notes (including notes payable to related parties of $ 878 and $ 850 as of September 30, 2025 and December 31, 2024, respectively) 1,045 910 PPP loan 1,386 1,376 Total current liabilities 23,540 57,129 Warrant liabilities at fair value 311 — Loans payable - related party at fair value 14,359 — Total liabilities 38,210 57,129 Commitments and contingencies (Note 7) Convertible Preferred Stock: Series A convertible preferred stock: $ 0.0001 par value – 0 shares authorized. issued and outstanding at September 30, 2025 and 4,350,314 shares authorized, issued and outstanding at December 31, 2024, (Liquidation preference $ 5,307 at December 31, 2024) — 5,231 Series B convertible preferred stock: $ 0.0001 par value – 0 shares authorized, issued and outstanding at September 30, 2025, and 5,293,175 shares authorized, issued and outstanding at December 31, 2024, (Liquidation preference $ 13,815 at December 31, 2024) — 13,701 Series C/C-1 convertible preferred stock: $ 0.0001 par value – 0 shares authorized, issued and outstanding at September 30, 2025, and 8,220,445 shares authori

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing